Thompson Davis & CO. Inc. Raises Stock Holdings in CareDx, Inc (NASDAQ:CDNA)

Thompson Davis & CO. Inc. lifted its holdings in shares of CareDx, Inc (NASDAQ:CDNA) by 6.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 16,050 shares of the company’s stock after acquiring an additional 950 shares during the period. Thompson Davis & CO. Inc.’s holdings in CareDx were worth $344,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Quarry LP purchased a new stake in shares of CareDx during the third quarter valued at approximately $27,000. Royce & Associates LP increased its position in CareDx by 0.3% in the third quarter. Royce & Associates LP now owns 393,286 shares of the company’s stock worth $12,280,000 after buying an additional 1,000 shares during the last quarter. Principal Financial Group Inc. increased its position in CareDx by 6.5% in the fourth quarter. Principal Financial Group Inc. now owns 18,984 shares of the company’s stock worth $406,000 after buying an additional 1,151 shares during the last quarter. Rhumbline Advisers increased its position in CareDx by 1.8% in the fourth quarter. Rhumbline Advisers now owns 81,201 shares of the company’s stock worth $1,738,000 after buying an additional 1,451 shares during the last quarter. Finally, Quest Partners LLC increased its position in CareDx by 37.8% in the third quarter. Quest Partners LLC now owns 5,611 shares of the company’s stock worth $175,000 after buying an additional 1,540 shares during the last quarter.

CareDx Stock Performance

NASDAQ:CDNA opened at $22.29 on Friday. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -8.26 and a beta of 1.87. CareDx, Inc has a 52-week low of $7.42 and a 52-week high of $34.84. The stock has a fifty day moving average of $22.69 and a 200 day moving average of $25.40.

Insider Activity at CareDx

In other CareDx news, Director Peter Maag sold 5,000 shares of CareDx stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the director now owns 330,024 shares of the company’s stock, valued at $8,250,600. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on CDNA shares. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and decreased their target price for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. StockNews.com lowered CareDx from a “buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright reaffirmed a “neutral” rating and issued a $26.00 price target on shares of CareDx in a report on Tuesday, January 14th. Finally, BTIG Research cut their price target on CareDx from $40.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $28.33.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.